41 completed, 7 recruiting, 4 terminated, 4 unknown. 62 Phase 2, 12 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 62 | Completed 41, Recruiting 7, Terminated 4, Unknown 4, Withdrawn 3, Active not recruiting 2, Not yet recruiting 1 |
| Phase 1 | 12 | Completed 6, Recruiting 3, Terminated 2, Withdrawn 1 |
Follow Sarcoma, Kaposi: new trials by email Literature Review of Sarcoma, Kaposi trials Research Report on Sarcoma, Kaposi
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| A Study of Propranolol to Treat Kaposi Sarcoma Propranolol - Kaposi Sarcoma | Phase 2 | Recruiting | AIDS Malignancy Consortium | 25 | 2026-08-31 | 2026-10-05 |
| Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV) CYT107 - Kaposi Sarcoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 55 | 2026-04-08 | 2026-08-25 |
| Propranolol for the Treatment of Kaposi Sarcoma in Adults Propranolol Hydrochloride - Kaposi Sarcoma | Phase 2 | Recruiting | Washington University School of Medicine | 25 | 2025-08-20 | 2026-04-06 |
| Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas CD146/HER2 CAR-T cells - Sarcoma, Sarcoma, Kaposi | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 60 | 2025-05-29 | 2025-07-15 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease Daratumumab SC - Lymphoma, Primary Effusion | Phase 2 | Recruiting | National Cancer Institute (NCI) | 40 | 2024-07-10 | 2026-10-16 |
| Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma Pembrolizumab + Lenvatinib - Kaposi Sarcoma, Classic Kaposi Sarcoma | Phase 2 | Withdrawn | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 2024-02-01 | 2026-01-22 | |
| Trial of Ixazomib for Kaposi Sarcoma Ixazomib Citrate, Quality-of-Life Assessment, Questionnaire Administration - Kaposi Sarcoma, Skin | Phase 2 | Active not recruiting | AIDS Malignancy Consortium | 41 | 2023-11-07 | 2026-11-02 |
| L19IL2/L19TNF in Skin Cancer Patients L19IL2/L19TNF - BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma | Phase 2 | Unknown | Philogen S.p.A. | 70 | 2023-03-09 | 2023-10-06 |
| Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma Abemaciclib - Kaposi Sarcoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 111 | 2021-09-29 | 2026-10-16 |
| Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma Talimogene laherparepvec - Kaposi Sarcoma | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 20 | 2021-01-01 | 2022-06-10 |
| A Study of sEphB4-HSA in Kaposi Sarcoma sEphB4-HSA - Kaposi Sarcoma | Phase 2 | Unknown | Vasgene Therapeutics, Inc | 65 | 2020-09-17 | 2024-05-02 |
| PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma PDS01ADC, M7824 - Kaposi Sarcoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2020-07-13 | 2026-10-16 |
| Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's Sarcoma Pembrolizumab - Kaposi Sarcoma, Progression, Disease | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 17 | 2018-07-01 | 2019-10-21 |
| Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma Laboratory Biomarker Analysis, Nelfinavir Mesylate - Recurrent Kaposi Sarcoma, Skin Kaposi Sarcoma | Phase 2 | Completed | AIDS Malignancy Consortium | 36 | 2017-03-13 | 2025-12-17 |
| Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial. Valganciclovir, Antiretroviral Combinations - Kaposi Sarcoma, Human Immunodeficiency Virus | Phase 2 | Completed | National Institute of Cancerología | 40 | 2015-10-01 | 2022-01-27 |
| Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma gamma secretase inhibitor PF-03084014, pharmacological study, laboratory biomarker analysis - AIDS-related Kaposi Sarcoma, HIV Infection | Phase 2 | Withdrawn | AIDS Malignancy Consortium | 2015-07-01 | 2015-07-23 | |
| Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT Tc 99m tilmanocept - Kaposi's Sarcoma | Phase 2 | Completed | Navidea Biopharmaceuticals | 5 | 2014-09-01 | 2016-09-27 |
| Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma ABC294640 - Diffuse Large B Cell Lymphoma, Kaposi Sarcoma | Phase 1 / Phase 2 | Withdrawn | RedHill Biopharma Limited | 2014-07-01 | 2017-12-07 |
Showing 20 of 62. Sign in to see all of them.
Acquired Immunodeficiency Syndrome (20) · HIV Infections (20) · AIDS-related Kaposi sarcoma (14) · Sarcoma (14) · Osteosarcoma (5) · Skin Neoplasms (5) · Chondrosarcoma (3) · Fibrosarcoma (3) · Hemangiosarcoma (3) · Leiomyosarcoma (3) · Neoplasms (3) · Neuroectodermal Tumors, Primitive, Peripheral (3) · Neurofibrosarcoma (3) · Sarcoma, Synovial (3)
DNA Virus Infections (62) · Herpesviridae Infections (62) · Infections (62) · Neoplasms by Histologic Type (62) · Neoplasms, Connective and Soft Tissue (62) · Neoplasms, Vascular Tissue (62) · Virus Diseases (62) · Neoplasms (59) · Sarcoma (48) · Immune System Diseases (32) · Genital Diseases (31) · Urogenital Diseases (31) · Blood-Borne Infections (27) · Communicable Diseases (27) · Immunologic Deficiency Syndromes (27)
Bevacizumab (3) · Nelfinavir (3) · Paclitaxel (3) · Valganciclovir (3) · Doxorubicin (2) · Etoposide (2) · Filgrastim (2) · Indinavir (2) · Interferon alpha-2 (2) · Nivolumab (2) · Propranolol (2) · Ritonavir (2) · Semaxinib (2) · Zidovudine (2) · pembrolizumab (2)
National Cancer Institute (NCI) (16) · AIDS Malignancy Consortium (7) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Assistance Publique - Hôpitaux de Paris (2) · Abbott (1) · Agouron Pharmaceuticals (1) · Anderson Clinical Research (1) · Baker Norton Pharmaceuticals (1) · Barbara Ensoli, MD, PhD (1) · Centro de Investigación en. Enfermedades Infecciosas, Mexico (1) · Clinical Solutions (1) · Dana-Farber Cancer Institute (1) · Eastern Cooperative Oncology Group (1) · Essen Biotech (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1)
United States (45) · France (4) · Mexico (3) · Uganda (3) · Brazil (2) · Italy (2) · Argentina (1) · Australia (1) · China (1) · Puerto Rico (1) · South Africa (1) · Spain (1) · United Kingdom (1) · Zimbabwe (1)
Robert Yarchoan, M.D. (5) · Ramya M Ramaswami, M.D. (3) · Jamie Hayden Von Roenn, MD (2) · Von Roenn JH (2) · Amy P Sing, MD (1) · Anna Wald, MD, MPH (1) · Ariela Noy, MD (1) · Bonnie C Abbruzzese, MS, RD, CCRA (1) · Camila MV Moniz, Doctor (1) · Carl Millner, M.D. (1) · Diana Ritchie, Dr. (1) · Eric Oksenhendler, M.D. (1) · Erin Reid, MD (1) · Grant Stewart, Dr (1)
PMID 17846226, PMID 18079362, PMID 18224669, PMID 18384551, PMID 19451429, PMID 22430271, PMID 25345840, PMID 25970141, PMID 27002157, PMID 27863194, PMID 32276276, PMID 32493198, PMID 34862247, PMID 35247913, PMID 35279271, PMID 37352498
U01CA121947 (3), P30CA008748 (2), U01CA070019 (2), UM1CA121947 (2), 2016 (1), 2UM1CA121947 (1), N01CM62206 (1), P30CA006516 (1), U01CA069856 (1)